Sarika Pandey

Asthma is one of the most common chronic diseases in the world which can cause considerable morbidity and a significant mortality.  Hence it is important to find out the different molecular diagnostic marker which can be use for early detection as well as treatment of patient with bronchial asthma.  GST biomarkers is likely become important not only as risk factors in the pathogenesis of asthma but also as determinants of responsiveness to treatment. This review represents the evidence reported  the association between gene polymorphism of glutathione-s-transferases (GSTs) GSTP1, GSTM1, GSTT1 gene and bronchial asthma. The data of Indian scenario demonstrate that the Polymorphism of Glutathione-s-transferase gene GSTT1, GSTM1 and GSTP1 is not significantly associated with Bronchial asthma in northern Indian population due to low sample size.

Lung cancer is the leading cause of cancer-related death accounting for 30% of all cancer-related deaths. The majority of lung cancer cases (80–90%) are due to smoking. Tobacco smoke and other environmental pollutants have been recognized as risk factors for more than 80–90% of cancer incidence in men. It has been reported that DNA methylation play important role in lung carcinogenesis . Several biomarkers from various sources such as genetics, proteomics, and epigenetic approaches are in use for clinical research purposes. DNA methylation analysis is one of the valuable source for cancer biomarkers. Since current diagnostic tools are either too costly or not sensitive enough to allow for early detection. Hence there is an urgent need of major technological advances in molecular oncology for the early detection of disease because early detection of lung cancer can change the outcome of disease.  This review summarizes current therapeutic knowledge in lung cancer, and recent advances in therapeutic strategies.